<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335497">
  <stage>Registered</stage>
  <submitdate>18/05/2010</submitdate>
  <approvaldate>21/05/2010</approvaldate>
  <actrnumber>ACTRN12610000410055</actrnumber>
  <trial_identification>
    <studytitle>The Effect of Anaesthetic Preconditioning on Lung Injury during One Lung Ventilation undergoing Transthoracic Esophagectomy</studytitle>
    <scientifictitle>Comparison of Plasma interleukin-6  between sevoflurane preconditioning and non-conditioning groups in patients undergoing transthoracic esophagectomy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>esophageal cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Oesophageal (gullet)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>In the group T and group T/S, propofol and remifentanil will be administered to end organ concentrations of 5.0 microg ml-1 and 4.0 ng ml-1, respectively, using a target-controlled infusion (TCI) pump (Orchestra, Fresenius Vial, France) from induction of anesthesia. 
 In the group T/S, 30 minutes before induction of one lung ventilation, total intravenous anesthesia(TIVA) will be stopped and replaced by 2 vol% sevoflurane. Namely, group T/S will receive propofol and remifentanil, followed by 30 min sevoflurane inhalation, and then TIVA again during one lung ventilation.</interventions>
    <comparator>Patients will be randomly assigned to 3 groups. One group will receive inhalational anesthesia with 2 vol% sevoflurane throughout the operation (group S), another group will receive total intravenous anesthesia (TIVA) with propofol 5 microgml-1 and remifentanil 4.0 ng ml-1 throughout the operation (group T) and the other group will receive TIVA and then shift to 2 vol% sevoflurane inhalation anesthesia for 30 minute before one lung ventilation, then  receive TIVA again (group T/S).</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>interleukin-6 plasma levels assessed by blood analysis</outcome>
      <timepoint>just before the start of one lung ventilation and  at end of operation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>blood malondialdehyde</outcome>
      <timepoint>just before the start of one lung ventilation and  at end of operation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>chest radiography</outcome>
      <timepoint>immediately prior to the operation and postoperative 1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>complications: anastomosis leakagewill be assessed clinically, arrhythmia by electrocardiogram (ECG), lung complications by physical signs and laboratory tests, and wound dehiscence will be assessed clinically</outcome>
      <timepoint>within 7 days, postoperatively, it will be assessed as  problems arise</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>American Society of Anaesthesiologists physical status I-III undergoing transthoracic esophagectomy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>high body temperature (over 37degrees celsius), increased levels of C-reactive protein (CRP) and white blood cell (WBC), administration nonsteroidal anti-inflammatory agent (NSAIDs) or corticosteroid within 3months, vital capacity (VC) or peak expiratoty volume at 1 minute (FEV1) less than 50% of expected.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed opaque envelopes</concealment>
    <sequence>computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/06/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>45</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Korea, Republic Of</country>
      <state>seoul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Jie Ae Kim</primarysponsorname>
    <primarysponsoraddress>50 Ilwon-dong, Kangnam-gu, Seoul, 135-710</primarysponsoraddress>
    <primarysponsorcountry>Korea, Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Samsung Medical Center, Clinical Research Development Program grant</fundingname>
      <fundingaddress>50 Ilwon-dong, Kangnam-gu, Seoul, 135-710</fundingaddress>
      <fundingcountry>Korea, Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Gunn Hee Kim</sponsorname>
      <sponsoraddress>50 Ilwon-dong, Kangnam-gu, Seoul, 135-710</sponsoraddress>
      <sponsorcountry>Korea, Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Pulmonary complication after one lung ventilation (OLV) is one of serious complications after transthoracic esophagectomy (TTE). The authors designed this study to investigate that the preconditioning of volatile anesthetics could decrease the production of pro-inflammatory cytokines or oxygen free radicals and decrease the development of pulmonary complications in the patients undergoing TTE. Forty-five adults undergoing TTE with OLV will be randomly assigned to receive sevoflurane anaesthesia (group S), total intravenous anaesthesia (TIVA) using propofol with remifentanil (group T), or sevoflurane preconditioning group (group T/S).The concentrations of plasma interleukin-6 (IL-6) and plasma malondialdehyde (MDA) will be assessed before and after OLV as the primary endpoint. The clinical outcome between group S and group T will be compared as the secondary endpoint.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Institutional review board</ethicname>
      <ethicaddress>50 Ilwon-dong, Kangnam-gu, Seoul 135-710 South Korea</ethicaddress>
      <ethicapprovaldate>28/04/2009</ethicapprovaldate>
      <hrec>2009-04-042</hrec>
      <ethicsubmitdate>23/04/2009</ethicsubmitdate>
      <ethiccountry>Korea, Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jie Ae Kim</name>
      <address>50 Ilwon-dong, Kangnam-gu, Seoul,135-710</address>
      <phone>+82 2 3410 0363</phone>
      <fax />
      <email>jakim0813@yahoo.com</email>
      <country>Korea, Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jie Ae Kim</name>
      <address>50 Ilwon-dong, Kangnam-gu, Seoul,135-710</address>
      <phone>+82 2 3410 0363</phone>
      <fax />
      <email>jakim0813@yahoo.com</email>
      <country>Korea, Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jie Ae Kim</name>
      <address>50 Ilwon-dong, Kangnam-gu, Seoul,135-710</address>
      <phone />
      <fax />
      <email />
      <country>Korea, Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>